NeoGenomics reported a 1% increase in consolidated revenue to $117 million for Q1 2022. Clinical Services revenue increased by 2%, while Pharma Services revenue decreased by 4%. The company experienced a net loss of $49 million, compared to a net loss of $22 million in the same period last year, due to increased operating expenses and amortization of acquired technology.